Heather G. Jørgensen

4.3k total citations · 1 hit paper
61 papers, 3.2k citations indexed

About

Heather G. Jørgensen is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Heather G. Jørgensen has authored 61 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Hematology, 36 papers in Genetics and 16 papers in Molecular Biology. Recurrent topics in Heather G. Jørgensen's work include Chronic Myeloid Leukemia Treatments (44 papers), Chronic Lymphocytic Leukemia Research (33 papers) and Eosinophilic Disorders and Syndromes (15 papers). Heather G. Jørgensen is often cited by papers focused on Chronic Myeloid Leukemia Treatments (44 papers), Chronic Lymphocytic Leukemia Research (33 papers) and Eosinophilic Disorders and Syndromes (15 papers). Heather G. Jørgensen collaborates with scholars based in United Kingdom, United States and Canada. Heather G. Jørgensen's co-authors include Tessa L. Holyoake, Elaine Allan, Joanne C. Mountford, Michael J. Alcorn, Susan M. Graham, Linda Richmond, Niove E. Jordanides, Mhairi Copland, Lucy J. Elrick and Ravi Bhatia and has published in prestigious journals such as Nature Communications, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Heather G. Jørgensen

61 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

2002 913 citations Heather G. Jørgensen, Elaine Allan et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Heather G. Jørgensen United Kingdom	27	2.3k	1.6k	1.0k	869	592	61	3.2k
Tetsuzo Tauchi Japan	30	1.5k 0.7×	911 0.6×	1.6k 1.6×	362 0.4×	621 1.0×	146	3.1k
Ji Yuan Wu United States	21	908 0.4×	803 0.5×	712 0.7×	496 0.6×	666 1.1×	44	2.1k
Matthias Mayerhofer Austria	32	1.1k 0.5×	820 0.5×	1.3k 1.3×	814 0.9×	446 0.8×	75	3.2k
Hirohiko Shibayama Japan	25	783 0.3×	501 0.3×	1.0k 1.0×	155 0.2×	463 0.8×	123	2.2k
Boris K. Lin United States	26	2.4k 1.0×	543 0.3×	2.8k 2.8×	130 0.1×	1.6k 2.7×	50	4.4k
Sonia Vallet United States	31	1.4k 0.6×	322 0.2×	1.8k 1.8×	97 0.1×	1.5k 2.5×	104	3.3k
Xiaoyang Ling United States	18	583 0.3×	703 0.4×	963 1.0×	62 0.1×	954 1.6×	35	2.4k
Hélène Lapillonne France	22	905 0.4×	495 0.3×	1.5k 1.4×	41 0.0×	285 0.5×	57	2.7k
Simone Boehrer Germany	24	620 0.3×	415 0.3×	1.0k 1.0×	27 0.0×	367 0.6×	68	1.7k
Sheeba K. Thomas United States	24	1.1k 0.5×	366 0.2×	1.1k 1.1×	26 0.0×	889 1.5×	161	2.0k

Countries citing papers authored by Heather G. Jørgensen

Since Specialization

Citations

This map shows the geographic impact of Heather G. Jørgensen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heather G. Jørgensen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heather G. Jørgensen more than expected).

Fields of papers citing papers by Heather G. Jørgensen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heather G. Jørgensen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heather G. Jørgensen. The network helps show where Heather G. Jørgensen may publish in the future.

Co-authorship network of co-authors of Heather G. Jørgensen

This figure shows the co-authorship network connecting the top 25 collaborators of Heather G. Jørgensen. A scholar is included among the top collaborators of Heather G. Jørgensen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heather G. Jørgensen. Heather G. Jørgensen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Huang, Xu, et al.. (2024). The MYC–NFATC2 axis maintains the cell cycle and mitochondrial function in acute myeloid leukaemia cells. Molecular Oncology. 18(9). 2234–2254. 1 indexed citations

Scott, Mary T., Wei Liu, Rebecca Mitchell, et al.. (2024). Activating p53 abolishes self-renewal of quiescent leukaemic stem cells in residual CML disease. Nature Communications. 15(1). 651–651. 7 indexed citations

Mannion, Niamh, Sandra Marmiroli, Heather G. Jørgensen, et al.. (2021). A KDM4A-PAF1-mediated epigenomic network is essential for acute myeloid leukemia cell self-renewal and survival. Cell Death and Disease. 12(6). 573–573. 24 indexed citations

Huang, Xu, et al.. (2021). Transcriptional Regulation by the NFAT Family in Acute Myeloid Leukaemia. SHILAP Revista de lepidopterología. 2(3). 556–571. 3 indexed citations

Zavatti, Manuela, Luca Braglia, Benedetta Accordi, et al.. (2021). Synergistic cytotoxicity of dual PI3K/mTOR and FLT3 inhibition in FLT3-ITD AML cells. Advances in Biological Regulation. 82. 100830–100830. 8 indexed citations

Horne, Gillian A., et al.. (2020). Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence. Journal of Clinical Medicine. 9(9). 2934–2934. 86 indexed citations

Jørgensen, Heather G., et al.. (2019). The Emerging Role of H3K9me3 as a Potential Therapeutic Target in Acute Myeloid Leukemia. Frontiers in Oncology. 9. 705–705. 50 indexed citations

Ganugula, Raghu, Meenakshi Arora, Ruedeekorn Wiwattanapatapee, et al.. (2017). Nano‐curcumin safely prevents streptozotocin‐induced inflammation and apoptosis in pancreatic beta cells for effective management of Type 1 diabetes mellitus. British Journal of Pharmacology. 174(13). 2074–2084. 89 indexed citations

Tarafdar, Anuradha, Lisa Hopcroft, Paolo Gallipoli, et al.. (2016). CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression. Blood. 129(2). 199–208. 56 indexed citations

10.

Scott, Mary T., Koorosh Korfi, Peter Saffrey, et al.. (2016). Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition. Cancer Discovery. 6(11). 1248–1257. 99 indexed citations

11.

Liu, Suhu, Tessa L. Holyoake, David A. Frank, et al.. (2016). Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia. Oncotarget. 7(32). 51651–51664. 12 indexed citations

12.

Venkatpurwar, Vinod, Susan Rhodes, Karin Oien, et al.. (2015). Drug- not carrier-dependent haematological and biochemical changes in a repeated dose study of cyclosporine encapsulated polyester nano- and micro-particles: Size does not matter. Toxicology. 330. 9–18. 11 indexed citations

13.

Allan, Elaine, Tessa L. Holyoake, Adam R. Craig, & Heather G. Jørgensen. (2011). Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells. Leukemia. 25(6). 985–994. 61 indexed citations

14.

Helgason, G. Vignir, Ashley Hamilton, Svetlana Myssina, et al.. (2010). Is Bcr-Abl expression relevant for the survival of cancer stem cells in chronic myeloid leukaemia (CML)?. British Journal of Haematology. 149. 72–72. 1 indexed citations

15.

Jiang, Xiaoyan, Donna L. Forrest, Franck E. Nicolini, et al.. (2010). Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate. Blood. 116(12). 2112–2121. 46 indexed citations

16.

Hatziieremia, Sophia, Niove E. Jordanides, Tessa L. Holyoake, Joanne C. Mountford, & Heather G. Jørgensen. (2009). Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib. Experimental Hematology. 37(6). 692–700. 24 indexed citations

17.

Strathdee, Gordon, Tessa L. Holyoake, Anton Parker, et al.. (2007). Inactivation of HOXA Genes by Hypermethylation in Myeloid and Lymphoid Malignancy is Frequent and Associated with Poor Prognosis. Clinical Cancer Research. 13(17). 5048–5055. 103 indexed citations

18.

Jørgensen, Heather G., Elaine Allan, Linda Richmond, et al.. (2005). Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. Leukemia. 19(7). 1184–1191. 57 indexed citations

19.

Elliott, Moira A., Heather G. Jørgensen, & Kevin D. Smith. (1998). Hypersialylation of α1‐Acid Glycoprotein in Rheumatoid Arthritis. Pharmacy and Pharmacology Communications. 4(11). 545–547. 5 indexed citations

20.

Jørgensen, Heather G., et al.. (1998). α1‐Acid Glycoprotein Derived from the Human Hepatoma Cell Line HepG2, and which Overexpresses Fucose, can Function as a Ligand for E‐selectin. Pharmacy and Pharmacology Communications. 4(2). 123–127. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact